melanoma Archives
Melanoma, anyone?
Dec. 19, 2023—Collegiate tennis and golf athletes aren’t using enough sunscreen according to a recent survey; meanwhile, the deadly skin cancer melanoma is on the rise.
Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors
Aug. 8, 2023—A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.
Study identifies key regulator of melanoma development
Jun. 29, 2023—Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.
Couple’s gift helps support immunotherapy research
Aug. 11, 2022—Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.
Melanoma treatment response
Feb. 24, 2022—Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.
Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma
Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.
Forty-three percent of melanoma patients have chronic complications from immunotherapies
Mar. 25, 2021—Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
Study reveals new strategy for reducing tumor growth, metastasis
Dec. 17, 2020—A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.
Study explores melanoma drug’s effectiveness
Apr. 23, 2020—A study by Vanderbilt research-ers supports the clinical development of a new second-line treatment for metastatic melanoma.
Potential second-line melanoma treatment identified
Aug. 15, 2019—A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.
Hot chemotherapy surgery helps save patient’s leg
Mar. 28, 2019—Tom Deweese can keep up with his grandchildren because of a highly specialized surgery using hot chemotherapy that saved his leg.
Entertainers’ support strengthens VICC melanoma research efforts
Apr. 12, 2018—Henry Paul and Dave Robbins, members of country music group BlackHawk, as well as southern rock band The Outlaws, recently donated $40,000 to Vanderbilt-Ingram Cancer Center (VICC) in support of melanoma research. Since 2006, the band members have generated more than $100,000 for VICC.